Loading…
IDEAYA Biosciences, Inc. is projected to rise to $30.88 by 2027, a +5% move from its current price of $29.28. IDYA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $28.72 | $29.28 | $29.84 | -0.02% |
| May 30 | $28.49 | $29.27 | $30.07 | -0.03% |
| May 31 | $28.31 | $29.27 | $30.25 | -0.05% |
| Jun 1 | $28.17 | $29.26 | $30.40 | -0.06% |
| Jun 2 | $28.03 | $29.26 | $30.53 | -0.08% |
| Jun 3 | $27.92 | $29.25 | $30.65 | -0.09% |
| Jun 4 | $27.81 | $29.25 | $30.77 | -0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $27.81 | $29.25 | $30.77 | -0.11% |
| Week 2 | $27.20 | $29.22 | $31.38 | -0.21% |
| Week 3 | $26.74 | $29.19 | $31.86 | -0.32% |
| Week 4 | $26.35 | $29.16 | $32.26 | -0.42% |
| Week 5 | $26.01 | $29.12 | $32.61 | -0.53% |
| Week 6 | $25.71 | $29.09 | $32.93 | -0.64% |
| Week 7 | $25.43 | $29.06 | $33.22 | -0.74% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
IDEAYA Biosciences, Inc. is a healthcare company focused on precision medicine oncology. It develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
IDEAYA offers Darovasertib, an oral, potent, and selective protein kinase C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company’s portfolio includes IDE849, a DLL3 antibody drug conjugate inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor; IDE397, a MAT2A inhibitor; IDE892, a PRMT5 inhibitor; IDE574, IDE275, and other preclinical programs focused on pharmacological inhibition and discovery engines.
IDEAYA was incorporated in 2015 and is headquartered in South San Francisco, California. It maintains strategic alliances with GlaxoSmithKline, Pfizer, Gilead Sciences, Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie, and has a clinical collaboration with AstraZeneca to evaluate IDE849.
IDEAYA Biosciences, Inc. (IDYA) is a Healthcare stock currently priced at $29.10 with a market capitalization of $2.56B and a rank of 1839.
The stock’s near-term technical picture shows a neutral stance, with the 30-day range spanning from $25.47 to $33.25 and the stock trading near key moving averages around $30.78 (SMA50) and $30.76 (SMA200). The 30-day support and resistance sit at $28.05 and $33.91, respectively.
Forecasts indicate a long-run upside path, with 2026 average price near $29.10 and a clear progression to higher values through 2050, culminating in an average of $161.48 and a max of $269.90. The sentiment shifts to bullish in the later years, with bullish labels appearing from 2029 onward.
A major floor 16.1% below — a decisive break under it would weaken the trend.
The nearest floor, 4.2% below — buyers have tended to step in here.
The nearest ceiling, 15.8% above — a clean break opens room to run.
A major ceiling 23.9% above — clearing it would confirm fresh momentum.
Key IDYA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IDYA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $29.38 | Sell | $29.20 | Buy |
| MA 10 | $28.95 | Buy | $29.06 | Buy |
| MA 20 | $28.70 | Buy | $29.22 | Buy |
| MA 50 | $30.59 | Sell | $30.30 | Sell |
| MA 100 | $32.22 | Sell | $30.98 | Sell |
| MA 200 | $30.83 | Sell | $30.30 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.30 | Neutral |
| Stoch RSI (14) | 81.74 | Sell |
| CCI (20) | 86.24 | Neutral |
| Williams %R (14) | -24.18 | Info |
| MACD (12,26,9) | 0.23 | Buy |
| ROC (12) | 3.39 | Buy |
| Bollinger %B (20,2) | 0.79 | Neutral |
| Stochastic %K (14) | 75.82 | Neutral |
| TRIX (15) | -0.32 | Sell |
| Awesome (5,34) | -0.51 | Sell |
| Ultimate (7,14,28) | 63.36 | Neutral |
| Momentum (10) | 1.16 | Buy |
| Aroon Osc (25) | -24.00 | Sell |
| Hull MA (9) | 29.53 | Sell |
| ADX (14) | 13.33 | Neutral |
| ATR (14) | 0.46 | Info |
The 30-day technical picture is Neutral, with a balanced momentum around the mid-$30s. RSI(14) sits at 50, and the stock sits near its short- to mid-term moving averages around $30.78 (SMA50) and $30.76 (SMA200).
The immediate trading range spans from $25.47 to $33.25 over the last 30 days. Support is identified at $28.05 and resistance at $33.91, suggesting a cautious range-bound trajectory in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $28.05 | $29.28 | $36.15 | 0% | Neutral | |
| $25.20 | $30.88 | $39.61 | +5% | Neutral | |
| $26.21 | $32.71 | $43.08 | +12% | Neutral | |
| $28.80 | $36.50 | $49.08 | +25% | Bullish | |
| $33.26 | $42.71 | $58.46 | +46% | Bullish | |
| $34.82 | $45.27 | $62.93 | +55% | Bullish | |
| $37.54 | $49.36 | $69.60 | +69% | Bullish | |
| $38.34 | $50.95 | $72.77 | +74% | Bullish | |
| $36.88 | $49.49 | $71.54 | +69% | Bullish | |
| $41.28 | $55.93 | $81.74 | +91% | Bullish | |
| $54.93 | $77.66 | $118.97 | +165% | Bullish | |
| $104.04 | $157.92 | $259.44 | +439% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $28.05 | $29.28 | $34.28 | +0.00% |
| June 2026 | $24.87 | $29.02 | $34.52 | -0.89% |
| July 2026 | $24.61 | $28.88 | $34.68 | -0.49% |
| August 2026 | $25.06 | $29.55 | $35.75 | +2.33% |
| September 2026 | $25.01 | $29.59 | $36.02 | +0.15% |
| October 2026 | $24.27 | $28.82 | $35.27 | -2.62% |
| November 2026 | $24.16 | $28.78 | $35.39 | -0.13% |
| December 2026 | $24.50 | $29.27 | $36.15 | +1.69% |
Click any year to see its month-by-month IDYA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect IDYA to range from $28.05 to $36.15 through 2026. The $29.28 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The IDYA price prediction for 2027 points to an average of $30.88 (low $25.20, high $39.61) — a potential gain of +5% on today's $29.28. A consolidation phase looks the most probable path here.
In 2028, IDYA is projected to trade between $26.21 and $43.08, averaging $32.71 — a potential gain of +12% from today's $29.28. That is up +6% on the projected 2027 average. Price action looks broadly range-bound.
IDEAYA Biosciences, Inc.'s 2029 outlook centres on $36.50, within a $28.80 to $49.08 range. That is up +12% on the projected 2028 average. That marks a +25% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, IDYA could reach as high as $58.46, with a base case around $42.71 and support toward $33.26 — roughly +46% from $29.28. Momentum favours further upside here.
Expect IDYA to range from $34.82 to $62.93 through 2031. The $45.27 average target implies a +55% move from current prices. That is up +6% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The IDYA price prediction for 2032 points to an average of $49.36 (low $37.54, high $69.60) — a potential gain of +69% on today's $29.28. Momentum favours further upside here.
In 2033, IDYA is projected to trade between $38.34 and $72.77, averaging $50.95 — a potential gain of +74% from today's $29.28. That is up +3% on the projected 2032 average. Buyers look set to stay in control over this stretch.
IDEAYA Biosciences, Inc.'s 2034 outlook centres on $49.49, within a $36.88 to $71.54 range. That is -3% versus the projected 2033 average. That marks a +69% change versus current levels. Momentum favours further upside here.
By 2035, IDYA could reach as high as $81.74, with a base case around $55.93 and support toward $41.28 — roughly +91% from $29.28. Buyers look set to stay in control over this stretch.
Expect IDYA to range from $54.93 to $118.97 through 2040. The $77.66 average target implies a +165% move from current prices. That is up +39% on the projected 2035 average. Momentum favours further upside here.
The IDYA price prediction for 2050 points to an average of $157.92 (low $104.04, high $259.44) — a potential gain of +439% on today's $29.28. Buyers look set to stay in control over this stretch.
Investing $1,000 in IDYA today (≈ 34.153005 IDYA) could be worth
$5,393.6
+$4,393.6 (+439%) by 2050 · US Dollar
Based on the average projected IDYA price of $157.92 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IDYAwould be worth at today's price.
$1,000 invested in IDYA on May 27, 2025 (≈ 51.493306 IDYA) would be worth
$1,507.72
+$507.72 (+50.8%) today · 1.51× · US Dollar
Based on a IDYA entry price of $19.42 vs. today's $29.28.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $29.65 | $987.52 | -1.2% |
| 1 month ago | $29.48 | $993.22 | -0.7% |
| 3 months ago | $31.9 | $917.87 | -8.2% |
| 6 months ago | $35.62 | $822.01 | -17.8% |
| 1 year ago | $19.42 | $1,507.72 | +50.8% |
| All time (5.0y) ago | $20.46 | $1,431.09 | +43.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IDYA forecast.
Our base-case forecast reaches $59.00 around 2040.
Implied market cap at $59.00: $5.18B
The multi-year forecast shows a transition to bullish sentiment starting in 2029, with 2029 at an average of $36.74 and a min of $28.82 and max of $49.82 (ROI 26.3). By 2030, the average is projected at $42.92 with a min of $33.18 and max of $59.28 (ROI 47.5). The forecast continues higher, with 2040 averaging $79.43 (min $55.41, max $123.43; ROI 172.9) and 2050 averaging $161.48 (min $104.36, max $269.90; ROI 454.9).
These figures indicate a long-run upside path, but as with all forecasts, they are estimates and not guarantees. Investors should weigh the bullish outlook for 2029–2050 against the inherent uncertainty in long-term equity forecasting.
Tap a question to reveal the answer.
According to the forecast, IDEAYA’s 2030 average price is $42.92, with a min of $33.18 and a max of $59.28, and an ROI of 47.5. The year is labeled bullish.
The forecast shows a bullish sentiment from 2029 onward, with rising averages through 2030, 2040, and 2050 (2030 avg $42.92; 2040 avg $79.43; 2050 avg $161.48) and an ultimate max of $269.90. However, these are estimates, not guarantees.
Yes, the forecast projects a max price of $123.43 by 2040 and $269.90 by 2050, indicating the potential to exceed $100 in the longer term.
Current price: $29.10. Market cap: $2.56B.
The 30-day range is $25.47 to $33.25. RSI(14) is 50. SMA50 is $30.78 and SMA200 is $30.76. Support is $28.05 and resistance is $33.91.
IDEAYA Biosciences, Inc. Community Discussion
0Share your IDEAYA Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.